Annual CFF
$1.87 M
+$1.55 M+476.00%
31 December 2023
Summary:
Barinthus Biotherapeutics annual cash flow from financing activities is currently $1.87 million, with the most recent change of +$1.55 million (+476.00%) on 31 December 2023. During the last 3 years, it has fallen by -$39.56 million (-95.48%). BRNS annual CFF is now -99.16% below its all-time high of $222.74 million, reached on 31 December 2021.BRNS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$465.00 K
+$107.00 K+29.89%
30 September 2024
Summary:
Barinthus Biotherapeutics quarterly cash flow from financing activities is currently $465.00 thousand, with the most recent change of +$107.00 thousand (+29.89%) on 30 September 2024. Over the past year, it has increased by +$419.00 thousand (+910.87%). BRNS quarterly CFF is now -99.62% below its all-time high of $121.81 million, reached on 01 March 2021.BRNS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$1.44 M
+$419.00 K+41.24%
30 September 2024
Summary:
Barinthus Biotherapeutics TTM cash flow from financing activities is currently $1.44 million, with the most recent change of +$419.00 thousand (+41.24%) on 30 September 2024. Over the past year, it has dropped by -$812.00 thousand (-36.14%). BRNS TTM CFF is now -99.46% below its all-time high of $265.56 million, reached on 01 June 2021.BRNS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BRNS Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +476.0% | +910.9% | -36.1% |
| 3 y3 years | -95.5% | +133.5% | -99.4% |
| 5 y5 years | - | - | - |
BRNS Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -99.2% | +476.0% | -72.5% | +133.5% | -99.4% | +193.4% |
| 5 y | 5 years | -99.2% | +476.0% | -99.6% | +133.5% | -99.5% | +193.4% |
| alltime | all time | -99.2% | +476.0% | -99.6% | +133.5% | -99.5% | +193.4% |
Barinthus Biotherapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $465.00 K(+29.9%) | $1.44 M(+41.2%) |
| June 2024 | - | $358.00 K(-28.8%) | $1.02 M(+48.1%) |
| Mar 2024 | - | $503.00 K(+361.5%) | $686.00 K(-63.4%) |
| Dec 2023 | $1.87 M(+476.0%) | $109.00 K(+137.0%) | $1.87 M(-16.7%) |
| Sept 2023 | - | $46.00 K(+64.3%) | $2.25 M(+2.1%) |
| June 2023 | - | $28.00 K(-98.3%) | $2.20 M(+1.3%) |
| Mar 2023 | - | $1.69 M(+249.0%) | $2.17 M(+568.6%) |
| Dec 2022 | $325.00 K | $484.00 K(>+9900.0%) | $325.00 K(-316.7%) |
| Sept 2022 | - | $0.00(0.0%) | -$150.00 K(-90.2%) |
| June 2022 | - | $0.00(-100.0%) | -$1.54 M(-101.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$159.00 K(-1866.7%) | $100.77 M(-54.8%) |
| Dec 2021 | $222.74 M(+437.6%) | - | - |
| Dec 2021 | - | $9000.00(-100.6%) | $222.74 M(-6.9%) |
| Sept 2021 | - | -$1.39 M(-101.4%) | $239.21 M(-9.9%) |
| June 2021 | - | $102.31 M(-16.0%) | $265.56 M(+62.7%) |
| Mar 2021 | - | $121.81 M(+639.1%) | $163.25 M(+294.0%) |
| Dec 2020 | $41.44 M | $16.48 M(-34.0%) | $41.44 M(+66.0%) |
| Sept 2020 | - | $24.95 M(>+9900.0%) | $24.95 M(>+9900.0%) |
| June 2020 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2020 | - | $0.00 | $0.00 |
FAQ
- What is Barinthus Biotherapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Barinthus Biotherapeutics?
- What is Barinthus Biotherapeutics annual CFF year-on-year change?
- What is Barinthus Biotherapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Barinthus Biotherapeutics?
- What is Barinthus Biotherapeutics quarterly CFF year-on-year change?
- What is Barinthus Biotherapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Barinthus Biotherapeutics?
- What is Barinthus Biotherapeutics TTM CFF year-on-year change?
What is Barinthus Biotherapeutics annual cash flow from financing activities?
The current annual CFF of BRNS is $1.87 M
What is the all time high annual CFF for Barinthus Biotherapeutics?
Barinthus Biotherapeutics all-time high annual cash flow from financing activities is $222.74 M
What is Barinthus Biotherapeutics annual CFF year-on-year change?
Over the past year, BRNS annual cash flow from financing activities has changed by +$1.55 M (+476.00%)
What is Barinthus Biotherapeutics quarterly cash flow from financing activities?
The current quarterly CFF of BRNS is $465.00 K
What is the all time high quarterly CFF for Barinthus Biotherapeutics?
Barinthus Biotherapeutics all-time high quarterly cash flow from financing activities is $121.81 M
What is Barinthus Biotherapeutics quarterly CFF year-on-year change?
Over the past year, BRNS quarterly cash flow from financing activities has changed by +$419.00 K (+910.87%)
What is Barinthus Biotherapeutics TTM cash flow from financing activities?
The current TTM CFF of BRNS is $1.44 M
What is the all time high TTM CFF for Barinthus Biotherapeutics?
Barinthus Biotherapeutics all-time high TTM cash flow from financing activities is $265.56 M
What is Barinthus Biotherapeutics TTM CFF year-on-year change?
Over the past year, BRNS TTM cash flow from financing activities has changed by -$812.00 K (-36.14%)